2025 Predictions: Will Certain Drug Classes Lose Their Specialty Status?

The 340B program has always operated inside a broader regulatory environment that does not hold still. In late 2024, two intersecting shifts - Medicare's Prescription Payment Plan changes and signals around drug category reclassification - created the kind of policy uncertainty that requires FQHCs and covered entities to think ahead rather than react.

This was the first in a three-part series of predictions from Remy's team, written in December 2024, on what the year ahead might bring for organizations operating in the 340B, TPA, and infusion space.

What the Medicare Prescription Payment Plan changes mean

Medicare's Prescription Payment Plan, created by the Inflation Reduction Act, does not reduce or cap what a beneficiary owes. It changes when and how they pay. Part D enrollees who opt in stop paying their cost sharing at the pharmacy counter and instead pay it back to their plan in capped monthly installments spread across the plan year. The total out-of-pocket amount is the same - the timing is smoothed.

The annual cap on Part D out-of-pocket spending is a separate Inflation Reduction Act provision. The two are often discussed together and are easy to conflate, but only the cap changes what a beneficiary ultimately pays.

The downstream effects for covered entities go beyond patient copays.

When payment models change, the way drugs are classified, reimbursed, and accounted for within 340B programs changes with them. Covered entities that do not monitor how their key drug categories are treated under evolving Medicare policy will find themselves making 340B purchasing decisions based on outdated assumptions.

Prediction: certain drug classes may not remain specialty drugs

The specific prediction is narrow but significant. To be clear about where it came from: this was Remy's own read of directional signals we were seeing in payer and PBM behavior in late 2024, not a published CMS position or an announced policy change. On that basis, we expected that drug classes including antiretrovirals, CGRP antagonists (used for migraine prevention), GLP-1 receptor agonists (used for diabetes and weight management), pancreatic enzymes, and PCSK9 inhibitors might not retain their specialty drug classification. Readers should check the current classification status of any drug class that matters to their program rather than relying on this article.

What reclassification would mean: Specialty drug status affects how drugs are priced, distributed, and reimbursed. If certain drug classes move out of specialty tiers, the potential effects include:

• Reduced patient acquisition costs and improved access, particularly for underserved populations
• Broader medication availability through standard pharmacy channels rather than specialty pharmacy networks
• Shifts in reimbursement rates that affect the economics of administering these drugs in an infusion or clinical setting
• Changes in how 340B discount eligibility applies to these drug categories

For FQHCs operating 340B programs, this is not purely good or bad news - it is a change that requires updated strategy.

Why tracking classification matters

The risk of inaction is not dramatic. No single reclassification event is likely to create a financial crisis for a well-run 340B program. The risk is cumulative: organizations that are not monitoring classification changes make decisions based on yesterday's rules while operating in today's environment. Small inefficiencies in purchasing strategy, contracting, and reimbursement accumulate over time.

Organizations operating in the 340B space need processes - not just awareness - for staying current on classification changes. That means designated responsibility for monitoring CMS and HRSA guidance, a regular cadence for reviewing how key drug categories are treated under current payer contracts, and a clear escalation path when something material changes.

The right posture: adaptable, not cautious

Regulatory uncertainty in the 340B space is not an argument for doing less. It is an argument for building more adaptable operating systems.

The covered entities that navigate this well are the ones that have strong compliance infrastructure, clear data visibility into their drug purchasing and patient eligibility, and relationships with advisors who can translate policy changes into operational decisions quickly.

Pulling back from infusion expansion or 340B optimization because the rules might change is not a conservative strategy - it is a strategy that concedes ground to competitors who are willing to stay engaged.

Read the rest of the series: Prediction 2 - why telephonic and virtual touch points are essential for medication access, and Prediction 3 - why specialty pharmacies are becoming a critical patient education channel.

If you want to work through what these regulatory shifts mean for your specific 340B program and purchasing strategy, contact Remy for a focused assessment.